IMMUNOASSAY MARKETS. Strategies and Trends. Forecasts by Instrument Type and by Application and by Country. With Multiplex and Point of Care Market Analysis, Executive Guides and including Customized Forecasting and Analysis. 2021 to 2025

OVERVIEW:

The workhorse of the diagnostic industry is finding new legs. The pandemic has created a new demand for rapid easily available diagnostics. Immunoassay is stepping up. Advances in genetic knowledge are creating new markets for immunoassay. Rapid diagnostics, point of care, biomarkers and consumer markets are all areas of expansion while traditional immunoassay maintains a strong position in the growing market for clinical diagnostics. We profile 44 companies, large and small, working in this area.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

• B.Sc. (Chemistry) University of BC
• M.B.A. (Finance and Policy) University of BC
• Market Research Seminar - Burke Institute
• Finance for Senior Executives - Harvard Business School

Table of Contents

• i. Immunoassay Market - Strategic Situation Analysis & COVID Impact

• ii. Guide for Executives, Marketing, Sales and Business Development Staff

• iii. Guide for Management Consultants and Investment Advisors

1. Introduction and Market Definition

• 1.1 Immunoassay Markets Definition In This Report
  • 1.1.1 Enzyme Based
  • 1.1.2 Immunofluorescence
  • 1.1.3 Chemiluminescence
  • 1.1.4 DNA/NAT
  • 1.1.5 RIA & Other
  • 1.1.6 Reagents/Kits, Analyzers, Software & Services
  • 1.1.7 Infectious Disease
  • 1.1.8 Auto Immune
  • 1.1.9 Endocrinology
  • 1.1.10 Oncology
  • 1.1.11 Cardiology
  • 1.1.12 Other Specialty
• 1.2 Market Definition
  • 1.2.1 Market Sizes
  • 1.2.2 Currency
  • 1.2.3 Years
• 1.3 Methodology
  • 1.3.1 Authors
  • 1.3.2 Sources
• 1.4 U.S. Medical Market and Clinical Laboratory Testing - Perspective

2. Industry Overview

• 2.1 Industry Participants
  • 2.1.1 IVD Supplier
  • 2.1.2 Independent lab specialized/esoteric
  • 2.1.3 Independent lab national/regional
  • 2.1.4 Independent lab analytical
  • 2.1.5 Public National/regional lab
  • 2.1.6 Hospital lab
  • 2.1.7 Physician lab
  • 2.1.8 Audit body
• 2.2 The Clinical Laboratory Market Segments
  • 2.2.1 Traditional Market Segmentation
  • 2.2.2 Laboratory Focus and Segmentation
  • 2.2.3 Hospital Testing Share
  • 2.2.4 Economies of Scale
    • 2.2.4.1 Hospital vs. Central Lab
  • 2.2.5 Physician Office Lab's
  • 2.2.6 Physician's and POCT
• 2.3 Immunoassay -Markets and Discussion
  • 2.3.1 Instruments - Genetics changes the picture
    • 2.3.1.1 RIA - A Technology Shows its Age
    • 2.3.1.2 Immunoassay vs. PCR vs. Sequencing - A See Saw Battle
    • 2.3.1.3 The Smart Shrinking Instrument - Serious Implications
    • 2.3.1.4 Research Funding and Capital Expense - Instrument Pooling
    • 2.3.1.4 Multiplex vs. POC - A Tradeoff Analysis
  • 2.3.2 Reagents and Kits - Genetics changes the picture
    • 2.3.1.1 Bigger Test Menus a Boon for Kit Market
  • 2.3.3 Physician Office Labs - A New Frontier
  • 2.3.4 Rapid and POCT to Threaten Instrument Markets
  • 2.3.5 OTC and DTC - Huge Market Potential
  • 2.3.6 Economies of Scale. Going Away?
  • 2.3.7 Lower Barriers to Entry for Instruments/Analyzers
  • 2.3.8 Miniturization and Technology Drive Acquisition

3. Market Trends

• 3.1 Factors Driving Growth
  • 3.1.1 Diagnostic Factors
  • 3.1.2 Changing Technologies Spur Early Instrument Retirement.
  • 3.1.3 Consumer Channels Open Wider.
  • 3.1.4 Immunity Technology Comes of Age
• 3.2 Factors Limiting Growth
  • 3.2.1 Increased Competition Lowers Price
  • 3.2.2 Threat from PCR Based Instruments.
  • 3.2.3 Lower Barriers to Entry.
  • 3.2.4 Wellness has a downside
• 3.3 Immunoassay Instrumentation
  • 3.3.1 Instrumentation Tenacity.
  • 3.3.2 Declining Cost of Instruments Changes Industry Structure.
  • 3.3.3 LISTING of CURRENT INSTRUMENT SPECIFICATIONS
  • 3.3.4 Immunoassay - CRISPR Diagnostics

4. Immunoassay Recent Developments

• 4.1 Recent Developments - Importance and How to Use This Section
  • 4.1.1 Importance of These Developments
  • 4.1.2 How to Use This Section
    • COVID-19 Portfolio to Accelerate At-Home Infectious Disease Testing
    • Roche Diagnostics Expanding Testing Portfolio in 2021
    • PerkinElmer Long-Term Outlook
    • Quidel Updates Outlook for C19 Testing
    • Dx Companies Look at Multiplex Tests for SARS-CoV-2, Influenza
    • Becton Dickinson and NAT Diagnostics Acquisition
    • New test diagnoses Lyme disease within 15 minutes
    • Multiplexed Immunoassay System Differentiates Malaria Species
    • ERBA Mannheim Unveils Next-Generation Nexus unit
    • Uman Diagnostics And Bio-Techne Announce Agreement For Neurofilament Light Assay
    • Software reduces variability in ELISA biomarker tests
    • Arrayit Corporation Allergy Testing Network Doubles
    • Expedeon Signs License Deal With Cell Guidance Systems for Biotin Tech
    • Efficacy Investigated for Electrochemiluminescence Immunoassay

5. Profiles of Key Companies

• Abbott Diagnostics
• Abcam
• Arlington Scientific
• Arrayit Corporation
• Awareness Technology
• Beckman Coulter Diagnostics
• Becton, Dickinson and Company
• Biocartis
• bioMérieux Diagnostics
• Bioneer Corporation
• Bio-Rad Laboratories, Inc
• BioTek Instruments
• Boditech Med, Inc
• Boster Biological Technology
• Diamedix (Erba Diagnostics)
• Diasorin S.p.A.
• Dynex Technologies
• Enzo Life Sciences, Inc.
• Eurofins Scientific
• FUJIFILM Wako Diagnostics
• Fujirebio
• Gold Standard Diagnostics
• Grifols
• Hycor Biomedical
• Immunodiagnostic Systems (IDS)
• Immunodiagnostik AG
• Inova Diagnostics
• JR Biomedical
• Luminex Corp
• Maxim Biomedical
• Meso Scale Discovery
• Millipore Sigma
• Mindray
• Molecular Devices
• MP Biomedical
• MyCartis
• Operon
• Ortho Clinical Diagnostics
• Perkin Elmer
• Qiagen Gmbh
• Quidel
• R&D Systems
• Randox Toxicology
• Roche Molecular Diagnostics
• Serametrix
• Siemens Healthineers
• Sysmex
• Tecan
• Thermo Fisher Scientific Inc.
• TOSOH Bioscience

6. The Global Market

• 6.1 Global Market by Country
  • 6.1.1 Global Market by Country Table
  • 6.1.2 Global Market by Country Chart
• 6.2 Global Market by Application
  • 6.2.1 Global Market by Application Table
  • 6.2.2 Global Market by Application Segment Growth Chart
  • 6.2.3 Global Market by Application Segment Annual Chart
  • 6.2.4 Global Market by Application Segment Base vs. Final
  • 6.2.5 Global Market by Application Base Year
  • 6.2.6 Global Market by Application Final Year
• 6.3 Global Market by Technology
  • 6.3.1 Global Market by Technology Table
  • 6.3.2 Global Market by Technology Segment Growth Chart
  • 6.3.3 Global Market by Technology Segment Annual Chart
  • 6.3.4 Global Market by Technology Segment Base vs. Final
  • 6.3.5 Global Market by Technology Base Year
  • 6.3.6 Global Market by Application Final Year

7. Global Market by Application

• 7.1 Endocrinology Applications
  • 7.1.1 Endocrinology Applications by Country Table
  • 7.1.2 Endocrinology Applications Growth Chart
• 7.2 Immune Applications
  • 7.2.1 Immune Applications by Country Table
  • 7.2.2 Immune Applications Growth Chart
• 7.3 Oncology Applications
  • 7.3.1 Oncology Applications by Country Table
  • 7.3.2 Oncology Applications Growth Chart
• 7.4 Infectious Disease Applications
  • 7.4.1 Infectious Disease Applications by Country Table
  • 7.4.2 Infectious Disease Applications Growth Chart
• 7.4 Cardiology Applications
  • 7.4.1 Cardiology Applications by Country Table
  • 7.4.2 Cardiology Applications Growth Chart
• 7.5 Other Applications
  • 7.5.1 Other Applications by Country Table
  • 7.5.2 Other Applications Growth Chart

8. Immunoassay by Technology

• 8.1 Enzyme
  • 8.1.1 Enzyme by Country Table
  • 8.1.2 Enzyme Growth Chart
• 8.2 Flourescence
  • 8.2.1 Flourescence by Country Table
  • 8.2.2 Flourescence Growth Chart
• 8.3 Chemiluminescence
  • 8.3.1 Chemiluminescence by Country Table
  • 8.3.2 Chemiluminescence Growth Chart
• 8.4 Nucleic Acid
  • 8.4.1 Nucleic Acid by Country Table
  • 8.4.2 Nucleic Acid Growth Chart
• 8.4 Rapid/POC
  • 8.4.1 Rapid/POC by Country Table
  • 8.4.2 Rapid/POC Growth Chart
• 8.5 Other Technology
  • 8.5.1 Other Technology by Country Table
  • 8.5.2 Other Technology Growth Chart

9. Vision of the Future of Immunoassay

Appendices

• I. United States Medicare System: 2021 laboratory Fees Schedule

Table of Tables

• TABLE 1 MEDICARE CLINICAL LAB EXPENDITURES ACTUAL & FORECAST 2014 TO 2024 ($BILLION)
• Table 2 Market Players by Type
• Table 3 Clinical Laboratory Departments and Segments
• Table 4 Laboratory Management Focus - Different Approaches
• Table 5 Key Segmentation Variables Going Forward
• Table 6 The Different Markets for Immunoassay
• Table 7 The Factors Driving Growth
• Table 8 Factors Limiting Growth
• Table 9 - Listing of Current Instrument Specifications
• Table 10 The Global Immunoassay Market by Country
• Table 11 Global Market by Application
• Table 12 Global Market by Technology
• Table 13 Endocrinology Immunoassay by Country
• Table 14 Immune Immunoassay by Country
• Table 15 Oncology Immunoassay by Country
• Table 16 Infectious Disease Immunoassay by Country
• Table 17 Cardiology Immunoassay by Country
• Table 18 Other Immunoassay by Country
• Table 19 Enzyme Immunoassay by Country
• Table 20 Flourescence Immunoassay by Country
• Table 21 Chemiluminescence Immunoassay by Country
• Table 22 Nucleic Acid Immunoassay by Country
• Table 23 Rapid/POC Immunoassay by Country
• Table 24 Other Technology Immunoassay by Country
• Table 25 2021 Clinical Lab Fee Schedule

Table of Figures

• Figure 1 Medicare Clinical Lab Expenditures 2014 to 2024 ($Million)
• Figure 2 Immunoassay - Country Sharea
• Figure 3 Chart of Growth by Application
• Figure 4 Chart of Segment by Year
• Figure 5 Chart of Base vs. Final
• Figure 6 Chart of Base Year by Application
• Figure 7 Chart of Final Year by Application
• Figure 8 Chart of Growth by Technology
• Figure 9 Chart of Technology Segment by Year
• Figure 10 Chart of Technology Base vs. Final
• Figure 11 Chart of Base Year by Technology
• Figure 12 Chart of Final Year by Technology
• Figure 13 Chart - Endocrine Segment vs Total Market Growth
• Figure 14 Chart - Immune Growth vs. Total
• Figure 15 Chart - Oncology vs Total
• Figure 16 Chart - Infectious Disease Immunoassay vs Total
• Figure 17 Chart - Cardiology Immunoassay vs total
• Figure 18 Chart - Other Immunoassay vs Total
• Figure 19 Chart - Enzyme Segment vs Total Market Growth
• Figure 20 Chart Flourescence Growth vs. Total
• Figure 21 Chart - Chemiluminescence vs Total
• Figure 22 Chart - Nucleic Acid Immunoassay vs Total
• Figure 23 Chart - Rapid/POC Immunoassay vs total
• Figure 24 Chart - Other Technology Immunoassay vs Total